Why Is HIMS & HERS HEALTH I A (HIMS) Stock Up Today?

Hims & Hers Health (HIMS) shares climbed 8.54% to $30.46, driven by a positive reaction to the company’s appointment of a new Chief Accounting Officer and broader market optimism regarding its peptide business. The stock opened with a modest gap and continued to rise throughout the session, reaching a high of $30.50 in the afternoon. This move reversed a recent downward trend, as the stock had declined 4.8% over the previous eight trading sessions.

What Happened

The primary catalyst for the rally was the announcement that Hims & Hers named CPA Jon Franklin, formerly of Rivian, as its Chief Accounting Officer. The company positioned the hire as a critical step in building the accounting infrastructure necessary to support its expansion into new medical specialties and global markets. Simultaneously, Citi analysts noted a tailwind from the company’s peptide offerings, although the firm maintains a bearish outlook with a projected 17% downside from current levels.

Legal developments also dominated the news cycle, with multiple law firms issuing notices to investors. Rosen Law Firm, Bronstein Gewirtz & Grossman LLC, and Kaplan Fox & Kilsheimer LLP all highlighted a lead-plaintiff deadline of November 2, 2026, for a securities class action covering purchases made between August 4, 2025, and July 29, 2026. Despite these legal warnings, trading activity remained directionally bullish, with call volume exceeding put volume in recent sessions.

What The Data Shows

The stock printed 32 fresh 52-week highs on October 9, 2026, signaling strong momentum despite the company’s unprofitable status. Fundamentals show a market capitalization of $6.9 billion, with trailing twelve-month revenue up 28.0% but earnings per share at negative $0.62. The stock carries a high beta of 2.43, indicating significant volatility relative to the broader market. Its 52-week range spans from $13.74 to $65.30.

Intraday, the stock opened at $28.36, a 1.1% gap up from the prior close, and traded as low as $28.31 before climbing to the session high of $30.50 at 2:35 PM ET. Volume stood at 7.0 million shares, which is 0.5 times the three-month daily average. Unusual options activity included three notable prints, with call premium totaling $610,000 compared to $264,000 in put premium. The largest single print was $353,000. Insider activity remains skewed toward selling, with 13 sales totaling $6.0 million in the last 90 days, including recent transactions by CFO Okupe Oluyemi and General Counsel Boughton Soleil.

What To Watch

Investors will monitor the November 2, 2026, lead-plaintiff deadline in the ongoing securities class action. Additionally, the market will watch how the new Chief Accounting Officer supports the company’s stated goals of expanding into new specialties and global markets, a strategy that remains central to the stock’s valuation narrative despite current unprofitability.